Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of IPO & Placements for Aequitas Research. At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%. 
Prior to Aequitas. I was heading Content Strategy for Smartkarma, along with covering IPOs & Placement. In an earlier life I have covered ASEAN property and the banking space in India.

Head of Research, IPOs & Placements

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>Rakuten plans to raise US$1.5bn through a follow-on offering for the purported reason of repaying debt. Given the company's past deal making record, the more likely outcome of the raising will be either a big acquisition or another round of smaller acquisitions/follow-on investments.&nbsp;</p><p>The deal scores a marginally positive score on our framework, with the positives being driven by the&nbsp;stock having a good long term-track record, while the elevated valuations vs longer-term averages and peers, accounts for most of the negatives. On the whole, given that the stock has already corrected by more than the dilution, combined&nbsp;with the added 3-5% discount being offered we would be inclined to take the deal.</p>

Rakuten plans to raise US$1.5bn through a follow-on offering for the purported reason of repaying debt. Given the company's past deal making record, the more likely outcome of the raising will be either a big acquisition or another round of smaller acquisitions/follow-on investments.&nbsp;The deal scores a marginally positive score on our framework, with the positives being driven by the&nbsp;stock having a good long term-track record, while the elevated valuations vs longer-term averages and peers, accounts for most of the negatives. On the whole, given that the stock has already corrected by more than the dilution, combined&nbsp;with the added 3-5% discount being offered we would be inclined to take the deal.

Probably stocking up for another round of acquistions